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ABSTRACT
The progression of prostate cancer (PCa) mainly occurs caused by androgens. There is a link 
between intratumoral steroidogenesis and castration-resistant prostate cancer. This study 
aimed to determine the mRNA expression of various steroidogenic enzymes (CYP17A1, 
CYP11A1, CYP19A1, HSD3B1, and AKR1C2) in metastatic and non-metastatic prostate 
cancer patients. This study was conducted at the Anatomical Pathology Laboratory and 
Urologi Division, Department of Surgery, Faculty of Medicine, Public Health and Nursing, 
Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta from September-
November 2017. Samples were taken from 30 paraffin blocks with adenocarcinoma of 
prostate, stained with hematoxylin-eosin (HE) and then classified into metastatic and non-
metastatic groups. Samples then underwent deparaffinization procedure and examination 
of mRNA expression of CYP17A1, CYP11A1, CYP19A1, HSD3B1, AKR1C2 genes using 
Real-Time PCR. The mean mRNA expressions of CYP11A1, CYP17A1, CYP19A1, 
HSD3B1, and AKR1C2 genes in the metastatic adenocarcinoma prostate group were 7.08, 
10.11, 3.94, 4.84 and 3.58, respectively. In the non-metastatic group, the mean mRNA 
expressions of CYP11A1, CYP17A1, CYP19A1, HSD3B1, and AKR1C2 genes were 4.62, 
9.45, 3.46, 2.68 and 4.92, respectively. The mean of mRNA expression of CYP11A1, 
CYP17A1, CYP19A1, and HSD3B1 genes were higher in the metastatic group than non-
metastatic adenocarcinoma prostate group. However, it was not statistically significant 
(p>0.05). The highest mRNA expression of steroidogenic enzymes was the CYP17A1 
gene. In conclusion, the mRNA expressions of CYP17A1, CYP11A1, CYP19A1, HSD3B1 
were higher in the metastatic prostate cancer patients compared to that in non-metastatic 
prostate cancer patients but statistically not significant.
ABSTRAK
Perkembangan kanker prostat (PCa) terutama terjadi karena androgen. Ada hubungan 
antara steroidogenesis intratumoral dan kanker prostat yang resisten-kastrasi. Penelitian 
ini bertujuan untuk mengkaji ekspresi mRNA dari berbagai enzim steroidogenik (CYP17A1, 
CYP11A1, CYP19A1, HSD3B1, dan AKR1C2) pada kanker prostat metastatik dan non-
metastatik. Penelitian ini dilakukan di Laboratorium Patologi Anatomi dan Divisi Urologi, 
Departemen Bedah, Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, 
Universitas Gadjah Mada/Rumah Sakit Umum Pusat Dr. Sardjito dari September-November 
2017. Sampel diambil dari 30 blok parafin dengan adenokarsinoma prostat dan diwarnai 
dengan pewarna hematoxylin-eosin (HE) untuk selanjutnya dikelompokkan menjadi 
kelompok metastasis dan non-metastasis. Sampel selanjutnya dideparafinisasi dan diukur 
ekspresi mRNAnya untuk gen-gen CYP17A1, CYP11A1, CYP19A1, HSD3B1, AKR1C2 
menggunakan Real-Time PCR. Ekspresi mRNA rata-rata untuk gen CYP11A1, CYP17A1, 
CYP19A1, HSD3B1, dan AKR1C2 pada kelompok prostat metastasis adenokarsinoma 
berturut-turut adalah 7,08, 10,11, 3,94, 4,84 dan 3,58. Pada kelompok non-metastatik, 
ekspresi mRNA rata-rata untuk gen-gen CYP11A1, CYP17A1, CYP19A1, HSD3B1, dan 
AKR1C2 berturut-turut adalah 4,62, 9,45, 3,46, 2.68 dan 4,92. Rata-rata ekspresi mRNA 
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gen CYP11A1, CYP17A1, CYP19A1, dan HSD3B1 lebih tinggi pada kelompok pasien 
prostat adenokarsinoma metastasis dibandingkan kelompok non-metastatik, tetapi secara 
statistik tidak signifikan (p> 0,05). Ekspresi mRNA tertinggi dari enzim steroidogenik adalah 
gen CYP17A1. Dapat disimpulkan, ekspresi mRNA dari CYP17A1, CYP11A1, CYP19A1, 
HSD3B1 lebih tinggi pada pasien kanker prostat metastatik dibandingkan non-metastatik 
tetapi secara statistik tidak signifikan.
Keywords: Prostate cancer - CYP17A1 - metastatic - non-metastatic - steroidogenesis, 
mRNA
INTRODUCTION
Prostate cancer (PCa) is the 4th most 
common type of malignancy in men 
worldwide after skin, lung and colon 
cancers. According to GLOBOCAN data in 
2008, prostate cancer ranked 5th in Indonesia. 
Based on data from the Indonesian Society 
of Urologic Oncology in 2011, there were 
971 people with prostate cancer in the period 
2006-2010 with the level of stage 4. Data 
obtained from Dr. Cipto Mangunkusumo 
General Hospital, Jakarta and Dharmais 
Cancer Hospital, Jakarta showed an increase 
in the number of patients with prostate 
cancer, with the number of patients per 
year around 70-80 new cases per year.1 As 
the second-leading cause of cancer-related 
deaths, prostate adenocarcinoma is the 
most commonly diagnosed non-cutaneous 
malignancy in men. Although early 
screening and detection has good prognosis, 
a significant number  of men seek treatment 
with advanced or metastatic disease.2
The pathway of androgen hormone 
activation has an important role in the 
development and progression of prostate 
cancer (FIGURE 1).3 Studies show 
the presence of intratumoral androgen 
biosynthesis remains active with increased 
activity of steroidogenesis enzymes in 
castrated tumors of the prostate. One of the 
factors that cause the increase in the activity 
of intratumoral androgen metabolism is 
epigenetic changes. In these cases, the 
process of methylation and change of the 
FIGURE 1. Androgen metabolic pathway4
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into object glass slides and stained with 
hematoxylin-eosin (HE). After microscopic 
reexamination of the samples, we divided 
the samples into two groups: non-metastatic 
and metastatic group. Later the samples 
underwent deparaffinization procedure, 
and the mRNA expression of CYP17A1, 
CYP11A1, CYP19A1, HSD3B1, AKR1C2 
genes from all of the samples were measured 
using Real-Time PCR.
Real-Time PCR
The study lasted for three months in the 
Anatomical Pathology Laboratory, Faculty 
of Medicine, Public Health and Nursing, 
Universitas Gadjah Mada, Yogyakarta. The 
course of study was as follows: PCa sample 
was extracted with Total RNA Kit GeneAll®. 
Real-Time PCR stage was processed using 
KAPA SYBR® fast qPCR Kit. Mapping of 
the samples was programmed within the PCR 
including the negative control. Mixtures 
of solution were made with composition 
as follows: 6.4 μL PCR-grade water, 10 
μL KAPA SYBR®, 0.4 μL forward primer 
(CYP17A1/CYP11A1/CYP19A1/HSD3B1/
AKR1C2), 0.4 μL reverse primer (CYP17A1/
CYP11A1/CYP19A1/HSD3B1/AKR1C2), 
0.4 μL deoxyuridine triphosphate (dUTP), 
0.4 μL KAPA RT MIX, 2 μL RNA template 
(TABLE 1). The mixtures were placed into 
48 well plates for every primer. Step of 
PCR and condition of DT lite real-time PCR 
system were presented in TABLE 2.
DNA structure in prostate cancer cells occur 
significantly in a number of newly identified 
steroidogenic enzyme regulatory genes: 
CYP17A1, CYP11A1, CYP19A1, HSD3B1, 
AKR1C2.4 
Current strategy in management of 
prostate cancer mainly involves using 
hormonal suppression therapy; however, 
major groups of patients develop castration-
resistant prostate cancer (CRPC). A few 
predictive markers of response to hormonal 
manipulation have been developed, but 
due to variation in inter-racial epigenetics, 
further understanding of epigenetics is 
needed to develop deliberate therapy on PCa. 
In this study, we examined each cascade of 
steroidogenesis in prostate cancer to evaluate 
our strategy in Indonesia on management of 
these cases.
MATERIALS AND METHODS
Patients
This study was conducted at Urology 
Division, Department of Surgery, Dr. 
Sardjito General Hospital, Yogyakarta, 
Indonesia from September-November 2017. 
The study was approved by the Medical 
and Health Research Ethics Committee 
of Faculty of Medicine, Public Health 
and Nursing, Universitas Gadjah Mada/
Dr. Sardjito General Hospital, Yogyakarta. 
Samples were taken from 30 paraffin blocks 
with adenocarcinoma of prostate. The 
samples were cut and the slices were placed 
TABLE 1. Sequence of the gene primer
Primer Forward sequence Reverse sequence
GADPH GCATCCTGG GCTACACTGAG TCCACCACCCTGTTGCTGTA
CYP19A1 CTGCAGACACTACTACTACA ATCCGAGTCACTGCTCTCAG
CYP11A1 AGACACTGAGACTCCACCCCA GACGGCCACTTGTACCAATGT
CYP17A1 AGCTCGTGGCTCTCTTGCTG CGCGATGTCTAGAGTTGCCA
HSD3B1 TTCCGCCCTCTCTGAGGTACT GGTCACGAAGTGGCGATTG
AKR1C2 GTAAAGCTCTAGAGGCCGT CACCCATGGTTCTTCTCGA
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TABLE 2. Step of PCR, condition of DT lite 
real-time PCR system (DNA- 
Technology)
Step of PCR Temperature Duration Cycle
Reverse transcription 42 oC 5 min -
Enzyme activation 95 oC 3 min -
Denaturation 95 oC 1-3 sec 40
Extension 60 oC ≥ 20 sec 40
RESULTS
The mean mRNA expressions of CY-
P11A1, CYP17A1, CYP19A1, HSD3B1, and 
AKR1C2 genes in the metastatic PCa group 
were 7.08, 10.11, 3.94, 4.84 and 3.58, respec-
tively. In the non-metastatic PCa group, the 
mean mRNA expressions of CYP11A1, CY-
P17A1, CYP19A1, HSD3B1, and AKR1C2 
genes were 4.62, 9.45, 3.46, 2.68 and 4.92, 
respectively (TABLE 3). The mean mRNA 
expressions of the CYP17A1 gene were the 
highest expression found in both non-meta-
static and metastatic PCa groups. 
TABLE 3. mRNA expression of CYP11A1, 
CYP17A1, CYP19A1, HSD3B1, 
and AKR1C2 genes
Genes PCa n Mean
CYP11A1
Metastatic 16 7.0813
Non-Metastatic 14 4.6250
CYP17A1
Metastatic 16 10.1113
Non-Metastatic 14 9.4536
CYP19A1
Metastatic 16 3.9425
Non-Metastatic 14 3.4643
HSD3B1
Metastatic 16 4.8469
Non-Metastatic 14 2.6800
AKR1C2 Metastatic 16 3.5800
Non-Metastatic 14 4.9221
There were no significant differences 
between the mean mRNA expressions of 
CYP11A1, CYP17A1, CYP19A1, HSD3B1, 
and AKR1C2 genes in the non-metastat-
ic PCa groups compared to the metastatic 
PCa groups. This result of groups mean is 
showed in TABLE 4.
TABLE 4. Mean comparison between groups
 Genes p Mean ± SEM*
CYP11A1 0.206 2.45 ± 1.89
CYP17A1 0.772 0.66 ± 2.25
CYP19A1 0.740 0.48 ± 1.42
HSD3B1 0.095 2.16 ± 1.25
AKR1C2 0.474 -1.34 ± 1.85
*SEM: standard error of the mean
DISCUSSION
Steroidogenesis requires specific 
hormones and can occur throughout the 
body. These steroid hormones depend on 
cholesterol, which is present in all tissues 
and is necessary for steroid biosynthesis.5 
Steroidogenic acute regulatory protein 
(STAR) transports cholesterol into the 
mitochondria in order to convert it to 
pregnenolone by cholesterol side-chain 
cleavage enzyme P450scc (CYP11A1).6 
This CYP11A1 activity is essential for 
steroidogenesis. During this process, 
pregnenolone is converted either by 
3β-hydroxysteroid dehydrogenase (HSD3B) 
to progesterone or by 17α-hydroxylase 
(CYP17A1) to 17α-OH-pregnenolone.7 
In this study, both non-metastatic and 
metastatic groups showed expression of 
CYP11A1, the mean expressions are 4.62 and 
7.08, respectively. The mean expressions of 
CYP17A1 in non-metastatic and metastatic 
group are 9.45 and 10.1, respectively.
One important regulator of the balance 
between androgens and estrogens is 
aromatase enzyme, encoded by CYP19A1 
gene (15q21.1), which is involved in 
circulating and tissue levels of these 
hormones in the prostate. Aromatase 
inhibitors have been found to block the 
production of estradiol and effective in 
breast cancer treatment. They pose another 
possibility for prostate cancer treatment, 
demonstrating that intraprostatic estradiol 
may be involved in the disease progression.8 
In this study, both non-metastatic and 
metastatic groups showed expression of 
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CYP19A1, and the mean expressions were 
3.46 and 3.94, respectively.
The HSD3B gene family consists 
of two genes and five pseudogenes, 
located in chromosome band 1p13.1. The 
enzyme 3b-hydroxysteroid dehydrogenase 
(HSD3B) deactivates dihydrotestosterone 
(DHT). The type I and type II enzymes are 
differentially expressed.4 It was reported that 
HSD3B expression increase in castration-
resistant prostate cancer (CRPC), causing 
increased androstenedione levels, which 
could generate testosterone.9 In this study, 
both non-metastatic and metastatic groups 
showed expression of HSD3B1 with the 
mean expressions were 2.68 and 4.84, 
respectively. In the previous study, variant 
allele of HSD3B1 in Chinese population 
has been reported by Wu et. al.10 In this 
population patients who have a variant of 
HSDB3B1 gene are more likely to progress 
to CRPC. This gene might also has a role in 
the prostate cancer progression in Indonesian 
population.
AKR1C2 is a member of the newly 
emerging Aldo-Keto reductase (AKR) gene 
family, which metabolize selected steroid 
hormones, such as progesterone, DHT and 
androstenedione as well as polyaromatic 
hydrocarbons. While sharing many similar 
characteristics such as genomic structure, 
amino acid and nucleotide sequences, 
these specific genes catalyze the reduction 
of selective steroids and are expressed in 
a variety of human tissues.11 In this study, 
both non-metastatic and metastatic groups 
showed expression of AKR1C2, and the mean 
expression was 4.92 and 3.58, respectively.
CONCLUSION
In this study, the mRNA expression 
of steroidogenic enzyme genes was not 
significantly increased in metastatic 
compared to the non-metastatic PCa groups. 
These results suggest that the presence 
or increased expression of steroidogenic 
enzyme genesare not clearly associated with 
metastatic PCa. Steroidogenic enzyme genes 
can also be seen in prostate cancer not merely 
in castration-resistant prostate cancer.
The highest mean mRNA expression 
of steroidogenic enzyme genes was the 
CYP17A1 gene, the mean mRNA expression 
were high both in non-metastatic and 
metastatic PCa groups. CYP17A1 gene 
could be a prognostic factor for prostate 
cancer in progression to castration-resistant 
prostate cancer. Further research on protein 
level with a multicenter study and a larger 
number of samples are necessary to clarify 
these results.
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